Bio-Rad Laboratories Vericheck ddPCR Empty-Full Capsid Kits for AAV serotypes 2 and 8

Bio-Rad Laboratories has launched its Vericheck ddPCR Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titre, genome titre and percentage of full capsids in purified or unpurified (crude lysate) samples.

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately 70% of the AAV gene therapy market, with AAV2 being the most prevalent serotype in clinical trials. Each AAV serotype exhibits unique properties that influence tissue tropism and therapeutic goal, allowing tailored approaches for gene therapy applications.

With the absolute quantification provided by Bio-Rad’s Droplet Digital PCR, the kits require minimal volumes of either crude lysate or purified samples to deliver robust, reproducible data for the assessment of critical quality attributes (CQAs) in AAV vector production. Designed and validated for Bio-Rad’s Droplet Digital PCR Systems, the kits provide consistent capsid content measurements across the AAV production process in line with regulatory guidelines, streamlining gene therapy development. They deliver a comprehensive solution for AAV vector characterisation, driving the development of safe and effective gene therapies.